Updated July 2026. Field status: Teplizumab (Tzield, Sanofi/Provention) remains the only approved disease-modifying therapy for T1D — FDA-approved November 2022 for delaying stage 3 T1D onset in stage-2 at-risk individuals by a median ~2–3 years. Peptide immunotherapy IMCY-0098 (Imcyse, proinsulin peptide with thiol-disulfide oxidoreductase motif) — Phase 1b (24 weeks, 41 adults with recent-onset T1D) showed favorable safety, no significant C-peptide decline in any dose group, and biomarker signals consistent with mechanism of action (BMC Medicine 2023; exploratory immune analysis 2024). Phase 2 planning underway. GAD-alum (Diamyd Medical) — DIAGNODE-2 Phase 2b trial demonstrated intralymphatic GAD-alum + oral vitamin D improved glycemic control and preserved beta-cell function in the HLA DR3-DQ2 genetic subgroup, reinforcing personalized-medicine approaches. Also active: ustekinumab and baricitinib repurposing trials, stem-cell derived islets, and multi-antigen peptide vaccines.
Tracking Teplizumab (Tzield) & Immune Tolerance Vaccines
Type 1 Diabetes (T1D) is an autoimmune disease where the immune system destroys insulin-producing beta cells in the pancreas, affecting 1.6 million Americans and 9 million globally. Unlike traditional vaccines that prevent infection, T1D vaccines are therapeutic immunotherapies that delay or prevent disease onset by inducing immune tolerance. In November 2022, the FDA approved Teplizumab (Tzield) - the first disease-modifying therapy for T1D, delaying clinical diagnosis by ~3 years (median 32 months) in at-risk individuals. This breakthrough represents decades of research into autoimmune disease prevention. This tracker monitors approved therapies, prevention vaccines for at-risk individuals (those with T1D autoantibodies), reversal vaccines for recent-onset T1D, and immune tolerance strategies including oral insulin, GAD65, and beta cell vaccines.